Millendo Therapeutics (NASDAQ:MLND) Stock Price Down 22.7%

Shares of Millendo Therapeutics Inc (NASDAQ:MLND) fell 22.7% during mid-day trading on Thursday . The company traded as low as $5.90 and last traded at $6.00, 792,418 shares changed hands during mid-day trading. An increase of 1,976% from the average session volume of 38,165 shares. The stock had previously closed at $7.76.

Several equities analysts have recently issued reports on MLND shares. Zacks Investment Research cut Millendo Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Wedbush reissued a “buy” rating and set a $24.00 price objective on shares of Millendo Therapeutics in a research report on Thursday, August 15th. Oppenheimer cut their target price on shares of Millendo Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $22.00 target price on shares of Millendo Therapeutics in a report on Monday, September 16th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $23.00.

The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.10 and a current ratio of 5.10. The company’s 50-day moving average price is $7.62 and its 200-day moving average price is $9.31. The firm has a market capitalization of $80.84 million, a PE ratio of -0.34 and a beta of 2.64.

Millendo Therapeutics (NASDAQ:MLND) last posted its earnings results on Wednesday, November 13th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.04). As a group, analysts anticipate that Millendo Therapeutics Inc will post -3.3 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in MLND. BlackRock Inc. boosted its position in shares of Millendo Therapeutics by 1,738.4% during the 2nd quarter. BlackRock Inc. now owns 468,342 shares of the company’s stock worth $5,414,000 after acquiring an additional 442,866 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Millendo Therapeutics by 62.2% in the 2nd quarter. Vanguard Group Inc. now owns 331,285 shares of the company’s stock valued at $3,829,000 after acquiring an additional 126,994 shares during the last quarter. International Biotechnology Trust PLC raised its position in shares of Millendo Therapeutics by 187.5% during the 2nd quarter. International Biotechnology Trust PLC now owns 177,825 shares of the company’s stock worth $2,056,000 after acquiring an additional 115,965 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Millendo Therapeutics by 100.3% during the 2nd quarter. Renaissance Technologies LLC now owns 208,864 shares of the company’s stock worth $2,414,000 after acquiring an additional 104,567 shares in the last quarter. Finally, AWM Investment Company Inc. raised its position in shares of Millendo Therapeutics by 288.1% during the 2nd quarter. AWM Investment Company Inc. now owns 77,629 shares of the company’s stock worth $897,000 after acquiring an additional 57,629 shares in the last quarter. 60.08% of the stock is owned by institutional investors and hedge funds.

Millendo Therapeutics Company Profile (NASDAQ:MLND)

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Recommended Story: Range Trading

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.